Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Estramustine-binding protein in meningioma.

A E Karlsson1, A T Bergenheim, P Björk

  • 1Department of Oncology, Umeå University, Sweden. Anna.Karlsson@onkologi.umu.se

Acta Neuropathologica
|August 12, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer in young adulthood - classifying the intensity of treatment.

Acta oncologica (Stockholm, Sweden)·2022
Same author

Age and surgical outcome of low-grade glioma in Sweden.

Acta neurologica Scandinavica·2018
Same author

The prognostic value of pre-treatment thrombocytosis in two cohorts of patients with non-small cell lung cancer treated with curatively intended chemoradiotherapy.

Neoplasma·2017
Same author

EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis.

Neuropathology and applied neurobiology·2017
Same author

Expression of LRIG1 is associated with good prognosis and human papillomavirus status in oropharyngeal cancer.

British journal of cancer·2014

Estramustine-binding protein was found in meningioma, suggesting a potential role for estramustine, a drug used for prostate cancer, in treating relapsing meningioma. Further research is warranted.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Estramustine-binding protein (EBP) presence correlates with estramustine efficacy in prostate cancer treatment.
  • Estramustine is a cytotoxic drug combining estradiol and nornitrogen mustard.

Purpose of the Study:

  • To investigate the expression and characteristics of estramustine-binding protein (EBP) in meningioma.
  • To assess the potential of estramustine for treating meningioma.

Main Methods:

  • Ligand-binding assays (Scatchard analysis) using [3H]estramustine.
  • Immunohistochemistry for EBP.
  • Radioimmunoassay (RIA) for EBP quantification.
  • Size exclusion chromatography and Western blot for EBP structural analysis.

Related Experiment Videos

Main Results:

  • Specific [3H]estramustine binding sites detected in meningioma with a dissociation constant of 22-26 nM.
  • EBP immunoreactivity in meningioma comparable to prostatic carcinoma.
  • Mean EBP concentration in meningioma: 159 ng/g tissue.
  • Meningioma EBP structure shows similarity to rat prostate EBP, with polypeptide components at 10, 14, and 16 kDa.

Conclusions:

  • Estramustine-binding protein is present in meningioma, with specific estramustine binding observed.
  • The findings suggest a potential therapeutic role for estramustine or similar drugs in relapsing meningioma.
  • Further studies are needed to elucidate EBP's role in meningioma growth and therapeutic potential.